Tumor acute myeloid leukemia

Cancers Multiple myeloma Non-Hodgkin s lymphoma Hodgkin s disease Acute myeloid leukemia Neuroblastoma Germ cell tumors Acute myeloid leukemia Acute lymphoblastic leukemia Chronic myeloid leukemia Myelodysplastic syndrome Myeloproliferative disorders Non-Hodgkin s lymphoma Hodgkin s disease Chronic lymphocytic leukemia Multiple myeloma... 

Enzymes Degrading Macromolecules. Enzymes that degrade macromolecules such as membrane polysaccharides, stmctural and functional proteins, or nucleic acids, have all shown oncolytic activity. Treatment strategies include the treatment of inoperable tumors with pepsin (1) antitumor activity of carboxypeptidase (44) cytotoxicity of ribonudease (45—47) oncolytic activity of neuraminidase (48—52) therapy with neuraminidase of patients with acute myeloid leukemia (53) antitumor activity of proteases (54) and hyaluronidase treatment in the management of human soHd tumors (55). 

Murphy M, Ahn J, Walker KK (1999) Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 13 2490-2501 Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S (1998) FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 241(1) 126-133 Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, Alvarez R, Schiavone EM, Eerrara F, Bresciani F, Weisz A, de Lera AR, Gronemeyer H, Altucci L (2005) Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nature Med 11 77-84... 

Over 70% of transplantations were carried out concerning lympho-granulematosis, lymphoma, and myeloma others are connected with testicular cancer, acute myeloid leukemia, solid tumors and other oncological diseases. The lethality related with transplantation (100-days lethality among the transplanted patients) was 2,3% (died 4 patients) within 5 years. At the beginning of 2006 56% of all transplanted patients did not have the signs of basic disease progression. 

Bhatia M, Davenport V, Cairo MS. 2007. The role of interleukin-11 to prevent chemotherapy-induced cytopenia in patients with solid tumors, lymphomas, acute myeloid leukemia and bone marrow failure syndromes. Leuk Lymph. 48 9-15. 

Mustjoki S, Sidenius N, Sier CF, Blasi F, Elonen E, Alitalo R, et al. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy. Cancer Res 2000 60(24) 7126-7132. 

Knapp W, Majdic O, Stockinger H, Bettelheim P, Liszka K, Koller U, et al. Monoclonal antibodies to human myelomonocyte differentiation antigens in the diagnosis of acute myeloid leukemia. Med Oncol Tumor Pharmacother 1984 l(4) 257-262. 

Alkylating agents have been implicated in the causation of secondary tumors, including acute myeloid leukemia, myelodysplastic syndromes (69), solid tumors (70,71), Hodgkin s disease (72,73), ovarian cancer (74,75), and gastric cancer (69). Survival from the time of diagnosis of secondary malignancies is usually very short (69). 

Vincristine is part of many chemotherapeutic regimens, based on its lack of myelosuppressive toxicity. It is used, for example, in the treatment of acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), lymphomas, neuroblastoma, brain tumors, and Wilms tumor. The generally recommended dose in adults is 1.4 mg/m /week intravenously (5). Some clinicians have recommended an absolute upper limit of 2 mg, but this limitation is still a matter of debate (6). The usual pediatric dosage is 1.5-2 mg/m, but for children weighing 10 kg or less or who have a body surface area less than 1 m, the manufacturers recommend that treatment should be begun at 0.05 mg/kg once a week (5). 

CD7 has the distinction of being the most frequently lost T subset marker, particularly on mycosis fungoides. i It is also present on non-T-cell malignancies including NK tumors and acute myeloid leukemia. It is detectable on paraffin sections only with difficulty. 

The MIC2 gene product is labeled CD99 and serves to regulate the interactions between intercellular adhesion molecules. It is found in many lymphoblastic leukemia/lymphomas, acute myeloid leukemias, some low-grade B-cell lymphomas, and a variety of solid tumors. 

Bergmann L, Maurer U, Weidmann E. Wilms tumor gene expression in acute myeloid leukemias. Leuk Lymphoma. 1997 25 435-443. 

Tumor type acute myeloid leukemia Antigen HER2/neu (ErbB-2) Tyrosine kinase Trastuzumab (humanized) None None... 

---